AUPH — Aurinia Pharmaceuticals Inc stock price and chart

AUPH

$17.33+2.54%

as of close, Oct 22, 2026

☾ AH $17.33 +2.54%

Aurinia Pharmaceuticals IncStock · HealthcareRussell 2000 · 0.06% of IWMNasdaq Composite · 0.006% of ONEQRussell 3000 · 0.003% of IWV

PeersMRNALLYMDTUNHJNJTMO

Share this page

Technical analysis2

Overlay lines0

Addendum charts0

VolumeEEEEEEEEEEEEEEEE

20162019202120242026

5.010.015.020.025.030.00100.0M$17.33

2026-10-22

Price$17.33

MA20$16.09

MA50$14.98

Vol3.4M

What would $1,000 invested in AUPH be worth today? →

AUPH returns: By year · By month · By week · Trailing

Key stats#

Price data

Price: $17.33
YTD price return: +8.65%
YTD total return: +8.65%
Next earnings: Nov 3, 2026
Market cap: 2.3B2018-03 436.2M2026-10 2.3B+428.6% over the window
Enterprise value: 2.2B
Shares outstanding: 133.1M2017-12 84.1M2026-06 133.1M+58.3% over the window
52W low: $11.48
52W high: $19.25
From 52W high: -9.97%
From 52W low: +50.96%
52W range: 75%

Volume

Rel volume: 0.94×
30D volume: 831K
30D $ vol: 13.7M

Fundamentals

Sales (ttm): 311.5M2016-12 173K2026-06 311.5M+179961.8% over the window
Sales/share: $2.342017-12 $0.002026-06 $2.34+46978.2% over the window
EPS (ttm): $2.292019-12 -$0.952026-06 $2.29-341.1% over the window
FCF (ttm): 175.1M2016-12 -18.7M2026-06 175.1M-1034.8% over the window
FCF/share: $1.322017-12 -$0.492026-06 $1.32-368.5% over the window
Book value/share: $4.622017-12 $2.122026-06 $4.62+118.3% over the window
Net margin: 100.84%2016-12 -13465.3%2026-06 100.8%-100.7% over the window
ROE: 51.09%2016-12 -64.8%2026-06 51.1%-178.8% over the window
ROA: 39.65%2016-12 -40.9%2026-06 39.6%-197.0% over the window
Current ratio: 5.422016-12 5.222026-06 5.42+3.8% over the window

Growth (CAGR, ttm) · 10Y

Sales: +19.77%2025-06-30 → 2026-06-30260.1M → 311.5M (+19.8% total)+24.83%2023-06-30 → 2026-06-30160.1M → 311.5M (+94.5% total)+40.17%2021-06-30 → 2026-06-3057.6M → 311.5M (+440.9% total)+120.22%2016-12-31 → 2026-06-30173K → 311.5M (+179961.8% total)
Net income: +418.62%2025-06-30 → 2026-06-3060.6M → 314.1M (+418.0% total)n/an/an/a
FCF: +89.49%2025-06-30 → 2026-06-3092.4M → 175.1M (+89.4% total)n/an/an/a
Shares: +1.08%2025-06-30 → 2026-06-30131.6M → 133.1M (+1.1% total)-2.47%2023-06-30 → 2026-06-30143.4M → 133.1M (-7.2% total)+0.71%2021-06-30 → 2026-06-30128.4M → 133.1M (+3.6% total)n/a

Per-share growth (CAGR, ttm) · 10Y

EPS: +433.17%2025-06-30 → 2026-06-30$0.43 → $2.29 (+432.6% total)n/an/an/a
Sales/share: +18.49%2025-06-30 → 2026-06-30$1.98 → $2.34 (+18.5% total)+27.99%2023-06-30 → 2026-06-30$1.12 → $2.34 (+109.7% total)+39.17%2021-06-30 → 2026-06-30$0.45 → $2.34 (+422.0% total)n/a
FCF/share: +87.47%2025-06-30 → 2026-06-30$0.70 → $1.32 (+87.4% total)n/an/an/a
Book value/share: +81.49%2025-06-30 → 2026-06-30$2.55 → $4.62 (+81.4% total)+19.10%2023-06-30 → 2026-06-30$2.74 → $4.62 (+69.0% total)+12.30%2021-06-30 → 2026-06-30$2.59 → $4.62 (+78.6% total)n/a
Price: +46.65%2025-10-22 → 2026-10-22$11.82 → $17.33 (+46.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+33.79%2023-10-23 → 2026-10-22$7.24 → $17.33 (+139.4% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-9.15%2021-10-22 → 2026-10-22$28.00 → $17.33 (-38.1% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+16.76%2016-10-21 → 2026-10-22$3.68 → $17.33 (+370.9% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +46.65%2025-10-22 → 2026-10-22$11.82 → $17.33 (+46.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+33.79%2023-10-23 → 2026-10-22$7.24 → $17.33 (+139.4% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-9.15%2021-10-22 → 2026-10-22$28.00 → $17.33 (-38.1% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+16.76%2016-10-21 → 2026-10-22$3.68 → $17.33 (+370.9% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 7.6×2018-03 -6.162026-10 7.34-219.1% over the window
Fwd P/E: 15.5×
P/S (ttm)Market cap ÷ TTM revenue.: 7.4×2018-03 1043.612026-10 7.40-99.3% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 3.8×2018-03 2.452026-10 3.75+53.0% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 13.2×2018-03 -10.592026-10 13.17-224.4% over the window
EV/EBITDA (fy): 12.9×
EV/Sales (ttm): 7.0×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 7.59%2017-12 -9.4%2026-06 7.8%-182.1% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 133.1M ÷ 131.6M. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.08%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.08%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($1.1B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.08%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($82.8M) ÷ today's market cap ($2.3B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 3.59%2017-12 -39.7%2026-06 3.7%-109.2% over the window
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $82.8M + TTM dividends $0) ÷ today's market cap ($2.3B). Same caveat as the cash buyback yield.: 3.59%2017-12 -39.7%2026-06 3.7%-109.2% over the window

Vs own 10Y history

P/S: 38th
P/B: 62nd

Bar = where today’s multiple sits in AUPH’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-10-22#

+2.54%

+3.59%

+3.96%

+13.05%

YTD

+8.65%

+46.62%

-38.11%

Financial statements

Open full AUPH financials →

Loading financial statements…

Ticker	Name	1M	1D
LLY	Eli Lilly and Company	+11.67%	+2.83%
JNJ	Johnson & Johnson	-0.59%	+3.81%
ABBV	AbbVie Inc.	+7.53%	+0.14%
UNH	UnitedHealth Group Incorporated Common Stock (DE)	+13.95%	+1.91%
MRK	Merck & Co. Inc.	-2.43%	-1.76%
NVS	Novartis AG	+10.61%	+1.52%
TMO	Thermo Fisher Scientific Inc.	+2.74%	-2.52%
AMGN	Amgen Inc.	+9.03%	+2.04%

AUPH — Aurinia Pharmaceuticals Inc price, chart and key statistics